Skip to main content
OpenTrials
Completed

NCT Number: NCT03737500

Standard Silicone-based vs. B-Lite® Light Weight Breast Implant After Total Mastectomy and Radiotherapy for Breast Cancer

Reconstructive surgery with breast implants after total mastectomy for breast cancer is invariably related to several possible complications, such as atrophy of surrounding tissues, skin thinning, capsular contracture, wound dehiscence and inframammary fold break. Such complications are promoted by elastic properties of tissues and their response to gravity forces exerted on breast implant weight, leading to microischaemic events. A poor cosmetic outcome may result up to breast implant exposure, and its removal may become necessary, thus compromising the quality of breast reconstruction. These complications are further favoured by post-mastectomy radiotherapy (PMRT), since irradiation could enhance microischaemia of peri-prosthetic soft tissues and muscle, with subsequent inadequate healing, fibrosis and thinning. Since PMRT has been associated to improved loco-regional control in node-positive breast cancer patients, its use has increased in recent years. On one hand, PMRT has improved loco-regional control but, on the other hand, it has increased the failure rate of breast reconstruction after total mastectomy. Change of timing in breast reconstruction (immediate vs. two-staged by use of tissue expander) has not decreased the complications rate after PMRT. Currently the failure rate of breast reconstruction after total mastectomy and PMRT ranges from 0% to 40%. The present study will recruit 80 participants affected by breast cancer candidated to total mastectomy with immediate breast reconstruction and subsequent PMRT or total mastectomy with reconstruction by tissue expander, subsequent PMRT and then definitive reconstruction with breast implant. Participants will be randomized in two experimental arms: 40 patients will receive final reconstruction by the use of standard silicone-based breast implant and the other 40 patients will receive B-Lite® light weight breast implant. Participants will be followed up at 1, 6, 12 and 24 months, and all patients will undergo breast MRI at 6 months. The primary goal of the present study is to evaluate the failure rate of breast reconstruction (i.e. the need of re-intervention for breast implant removal). Secondary end-points include the overall complications rate, MRI evaluation of breast implant and surrounding tissues, cosmetic outcomes and quality of life including participants' satisfaction with breast reconstruction.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Breast Unit - Istituti Clinici Scientifici Maugeri Spa SB

Pavia, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Breast cancer diagnosis with indication of total mastectomy and breast reconstruction
  • Indication of post-mastectomy radiation therapy
  • Availability to be followed up for 24 months
  • Signature of informed consent

Exclusion criteria

  • Patients candidated to breast-conserving surgery
  • Contraindicated breast reconstruction (severe comorbidities, unfavourable survival outcome expected, distant metastases)
  • Patients affected by other solid malignancies
  • Pregnancy
  • Participation to other clinical studies in the last three months

Treatment and study plan

B-Lite® light weight breast implant

Device

Definitive breast reconstruction after total mastectomy by the use of B-Lite® light weight breast implant

Standard silicone-based breast implant

Device

Definitive breast reconstruction after total mastectomy by the use of silicone-based breast implants commonly used in our institution

Primary outcomes

  1. Failure rate of breast reconstruction

    Time frame: 24 months

    Need of re-intervention for breast implant removal for any cause (such as breast implant exposure)

Secondary outcomes

  1. Overall complications rate

    Time frame: 24 months

    Occurrence of any complication at any time point, such as: capsular contracture, wound dehiscence, skin/soft tissues necrosis, inframammary fold break, implant exposure treated conservatively, hematoma, peri-prosthetic fluid collection, wound/implant infection

  2. Magnetic resonance imaging (MRI) of breast implant and surrounding tissues

    Time frame: 6 months

    MRI evaluation for skin/soft tissues thinning, capsular contracture, implant break, chronic seroma

  3. Change in cosmetic outcome

    Time frame: 1, 6, 12, 24 months

    Objective evaluation of cosmetic outcome by jugular-nipple/areola complex (NAC) and NAC-inframammary fold distances to evaluate symmetry, objective evaluation of plastic surgeon with serial photographs

  4. Change in Quality of life (QoL) measured with BIBCQ

    Time frame: 6, 12, 24 months

    QoL evaluation included patient's satisfaction with breast reconstruction using the Body Image after Breast Cancer Questionnaire (BIBCQ)

  5. Change in Quality of life (QoL) measured with BREAST-Q

    Time frame: 6, 12, 24 months

    QoL evaluation included patient's satisfaction with breast reconstruction, using the BREAST-Q score

Sponsors and collaborators

Lead sponsor

Istituti Clinici Scientifici Maugeri SpA

Other

Registry information

Official study title

Standard Silicone-based Breast Implant vs. B-Lite® Light Weight Breast Implant for Reconstructive Surgery After Total Mastectomy and Post-Mastectomy Radiotherapy for Breast Cancer: a Randomized Clinical Trial

Acronym: BLITE-01

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Nov 9, 2018
Registry last updated
Mar 20, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.